These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 30666506)

  • 1. Industry's Giant Leap Into Cellular Therapy: Catalyzing Chimeric Antigen Receptor T Cell (CAR-T) Immunotherapy.
    Ittershagen S; Ericson S; Eldjerou L; Shojaee A; Bleickardt E; Patel M; Taran T; Anak O; Hall C; Leung M; Roccoberton D; Salmon F; Fuchs M; Romanov V; Lebwohl D
    Curr Hematol Malig Rep; 2019 Feb; 14(1):47-55. PubMed ID: 30666506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma.
    Ali S; Kjeken R; Niederlaender C; Markey G; Saunders TS; Opsata M; Moltu K; Bremnes B; Grønevik E; Muusse M; Håkonsen GD; Skibeli V; Kalland ME; Wang I; Buajordet I; Urbaniak A; Johnston J; Rantell K; Kerwash E; Schuessler-Lenz M; Salmonson T; Bergh J; Gisselbrecht C; Tzogani K; Papadouli I; Pignatti F
    Oncologist; 2020 Feb; 25(2):e321-e327. PubMed ID: 32043764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19.
    Braendstrup P; Levine BL; Ruella M
    Cytotherapy; 2020 Feb; 22(2):57-69. PubMed ID: 32014447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tisagenlecleucel in Acute Lymphoblastic Leukemia: A Review of the Literature and Practical Considerations.
    Halford Z; Anderson MK; Bennett LL; Moody J
    Ann Pharmacother; 2021 Apr; 55(4):466-479. PubMed ID: 32762363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autologous cryopreserved leukapheresis cellular material for chimeric antigen receptor-T cell manufacture.
    Tyagarajan S; Schmitt D; Acker C; Rutjens E
    Cytotherapy; 2019 Dec; 21(12):1198-1205. PubMed ID: 31837735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.
    Jain T; Bar M; Kansagra AJ; Chong EA; Hashmi SK; Neelapu SS; Byrne M; Jacoby E; Lazaryan A; Jacobson CA; Ansell SM; Awan FT; Burns L; Bachanova V; Bollard CM; Carpenter PA; DiPersio JF; Hamadani M; Heslop HE; Hill JA; Komanduri KV; Kovitz CA; Lazarus HM; Serrette JM; Mohty M; Miklos D; Nagler A; Pavletic SZ; Savani BN; Schuster SJ; Kharfan-Dabaja MA; Perales MA; Lin Y
    Biol Blood Marrow Transplant; 2019 Dec; 25(12):2305-2321. PubMed ID: 31446199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials.
    Tyagarajan S; Spencer T; Smith J
    Mol Ther Methods Clin Dev; 2020 Mar; 16():136-144. PubMed ID: 31988978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia.
    Vairy S; Garcia JL; Teira P; Bittencourt H
    Drug Des Devel Ther; 2018; 12():3885-3898. PubMed ID: 30518999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation.
    Kansagra AJ; Frey NV; Bar M; Laetsch TW; Carpenter PA; Savani BN; Heslop HE; Bollard CM; Komanduri KV; Gastineau DA; Chabannon C; Perales MA; Hudecek M; Aljurf M; Andritsos L; Barrett JA; Bachanova V; Bonini C; Ghobadi A; Gill SI; Hill J; Kenderian S; Kebriaei P; Nagler A; Maloney D; Liu HD; Shah NN; Kharfan-Dabaja MA; Shpall EJ; Mufti GJ; Johnston L; Jacoby E; Bazarbachi A; DiPersio JF; Pavletic SZ; Porter DL; Grupp SA; Sadelain M; Litzow MR; Mohty M; Hashmi SK
    Biol Blood Marrow Transplant; 2019 Mar; 25(3):e76-e85. PubMed ID: 30576834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tisagenlecleucel, an approved anti-CD19 chimeric antigen receptor T-cell therapy for the treatment of leukemia.
    Liu Y; Chen X; Han W; Zhang Y
    Drugs Today (Barc); 2017 Nov; 53(11):597-608. PubMed ID: 29451276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kymriah® (tisagenlecleucel) - An overview of the clinical development journey of the first approved CAR-T therapy.
    Awasthi R; Maier HJ; Zhang J; Lim S
    Hum Vaccin Immunother; 2023 Dec; 19(1):2210046. PubMed ID: 37185251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [CAR T-cell therapy for malignant B-cell lymphoma : A new treatment paradigm].
    Balke-Want H; Borchmann P
    Internist (Berl); 2021 Jun; 62(6):589-596. PubMed ID: 34152469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
    Pehlivan KC; Duncan BB; Lee DW
    Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leukapheresis and Tisagenlecleucel Manufacturing Outcomes in Patients Age <3 Years with Relapsed/Refractory Acute Lymphoblastic Leukemia.
    Fong D; Tiwari R; Acker C; Clough L; Willert J
    Transplant Cell Ther; 2023 Sep; 29(9):579.e1-579.e10. PubMed ID: 37311511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New Era of Immunotherapy in Pediatric Brain Tumors: Chimeric Antigen Receptor T-Cell Therapy.
    Wu WT; Lin WY; Chen YW; Lin CF; Wang HH; Wu SH; Lee YY
    Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33673696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tisagenlecleucel Therapy: Nursing Considerations for the Outpatient Setting.
    Cunningham K; DiFilippo H; Henes K; Irwin LL; Napier E; Weber E
    Semin Oncol Nurs; 2021 Aug; 37(4):151178. PubMed ID: 34340892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential of CAR T therapy for relapsed or refractory pediatric and young adult B-cell ALL.
    Forsberg MH; Das A; Saha K; Capitini CM
    Ther Clin Risk Manag; 2018; 14():1573-1584. PubMed ID: 30233192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in Chimeric Antigen Receptor T-Cell Therapies for Solid Tumors.
    Baybutt TR; Flickinger JC; Caparosa EM; Snook AE
    Clin Pharmacol Ther; 2019 Jan; 105(1):71-78. PubMed ID: 30406956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia.
    Zou Y; Xu W; Li J
    J Hematol Oncol; 2018 Nov; 11(1):130. PubMed ID: 30458878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric antigen receptor T cell therapy comes to clinical practice.
    Wall DA; Krueger J
    Curr Oncol; 2020 Apr; 27(Suppl 2):S115-S123. PubMed ID: 32368181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.